CJC 1295 No DAC + Ipamorelin Blend

99%+ Purity USA Tested

Research Use Only. Not for Human or Veterinary Use

CJC-1295/Ipamorelin: Dual GHRH-receptor ligand research blend, ≥99% purity. Lyophilized powder for laboratory use.

$90.00

26 in stock

Peptide Name	CJC-1295 (without DAC)
CAS Number	863288-34-0
Molecular Formula	C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight	3367.97 g/mol
Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Appearance	White lyophilized powder
Purity	≥99% (HPLC)
— Ipamorelin —
Peptide Name	Ipamorelin
CAS Number	170851-70-4
Molecular Formula	C₃₈H₄₉N₉O₅
Molecular Weight	711.85 g/mol
Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Appearance	White lyophilized powder
Purity	≥99% (HPLC)
Blend Storage	-20°C, desiccated, protected from light
Solubility	Soluble in sterile water or PBS

This product is not intended for human or animal use. For scientific research only.

VivePeptides provides detailed analytical results including High-Performance Liquid Chromatography (HPLC) and mass spectrometry data for all peptides. These reports confirm peptide purity, composition, and molecular accuracy, giving researchers full transparency and confidence in the materials used for their studies.

VIEW COA

VivePeptides peptides should be stored in a cool, dry environment and protected from light and moisture. Lyophilized peptides are best kept refrigerated or frozen until use to maintain stability. Once reconstituted for research purposes, peptides should be stored according to standard laboratory protocols, typically under refrigeration, and handled using proper aseptic techniques to preserve integrity throughout the study period.

OVERVIEW

What Is CJC-1295 No DAC + Ipamorelin Blend?

The CJC-1295 No DAC + Ipamorelin blend combines two complementary growth hormone-related research peptides into a single formulation. CJC-1295 No DAC (also known as Modified GRF 1-29) is a synthetic GHRH analog consisting of 29 amino acids with four amino acid substitutions that enhance metabolic stability. Ipamorelin is a selective pentapeptide growth hormone secretagogue receptor (GHS-R) agonist that mimics the action of ghrelin at the pituitary.

This CJC-1295 ipamorelin blend is designed for CJC-1295 growth hormone research studying the synergistic effects of simultaneous GHRH receptor and GHS-R activation. The CJC-1295 No DAC peptide stimulates GH release through the GHRH pathway, while ipamorelin engages the ghrelin/GHS-R pathway — two distinct but complementary mechanisms for promoting pulsatile growth hormone secretion. This dual-pathway approach has made the CJC-1295 ipamorelin blend one of the most popular research combinations for studying growth hormone axis regulation. Buy CJC-1295 ipamorelin from VivePeptides for ≥99% purity from a trusted USA supplier.

Dual GH Secretagogue Blend

GHRH analog + GHS-R agonist for synergistic GH axis research

≥99% HPLC Purity

Each component verified via high-performance liquid chromatography

USA Tested & Verified

Third-party analytical testing performed in USA laboratories

RESEARCH

CJC-1295 No DAC + Ipamorelin Mechanism of Action in Research

The CJC-1295 ipamorelin blend mechanism involves two distinct but synergistic pathways converging on pituitary somatotroph cells. CJC-1295 ipamorelin research has explored how simultaneous activation of these pathways amplifies growth hormone release in research models.

GHRH Receptor Pathway (CJC-1295 No DAC)

CJC-1295 No DAC binds to the GHRH receptor on pituitary somatotroph cells, activating the Gs-cAMP-PKA signaling cascade. This pathway promotes transcription of the GH gene and stimulates GH secretion from existing granule stores. The four amino acid substitutions in CJC-1295 No DAC (Ala2→D-Ala, Asn8→Ala, Ala15→Ala, Met27→Leu) provide resistance to enzymatic degradation while maintaining receptor binding affinity. CJC-1295 growth hormone research has documented pulsatile GH release patterns following GHRH-R activation.

GHS-R/Ghrelin Receptor Pathway (Ipamorelin)

Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin. This pathway signals through Gq-phospholipase C-IP3 cascades, increasing intracellular calcium and promoting GH vesicle exocytosis. Ipamorelin is notable for its selectivity — unlike other GHS-R agonists, research indicates it produces minimal effects on ACTH, cortisol, or prolactin in research models (Raun et al., Endocrinology, 1998).

Synergistic Amplification

CJC-1295 ipamorelin research demonstrates that simultaneous GHRH-R and GHS-R activation can produce synergistic GH release exceeding the sum of individual responses. This synergy reflects the convergence of cAMP and calcium signaling pathways on common GH secretory mechanisms within somatotroph cells. —

COMPARISON

CJC-1295 No DAC + Ipamorelin vs Standalone CJC-1295: Research Comparison

This comparison helps researchers determine whether the blend or standalone CJC-1295 No DAC is more appropriate for their specific experimental design.

Feature	CJC-1295 No DAC + Ipamorelin Blend	CJC-1295 No DAC Standalone
Components	CJC-1295 No DAC + Ipamorelin	CJC-1295 No DAC only
Receptor Targets	GHRH-R + GHS-R (dual pathway)	GHRH-R only (single pathway)
GH Release Pattern	Synergistic, amplified pulsatile release	Standard GHRH-mediated pulsatile release
Selectivity	Both components selective for GH axis	Selective for GHRH pathway
Research Application	Synergy studies, dual-pathway GH research	Single-pathway GHRH research
Dose Optimization	Pre-blended for convenience	Flexible individual dosing
Complexity	Two-component system	Single-component system

The CJC-1295 ipamorelin blend is ideal for researchers studying dual-pathway GH axis activation and synergistic GH release mechanisms. Standalone CJC-1295 No DAC is preferred when isolating GHRH-R pathway contributions. Both are available from VivePeptides at CJC-1295 ipamorelin purity of ≥99%.

RESEARCH STUDIES

CJC-1295 No DAC + Ipamorelin Research Applications & Published Studies

CJC-1295 ipamorelin research draws from the published literature on each component peptide and their synergistic interaction in GH axis studies.

GHRH Analog Pharmacology

CJC-1295 growth hormone research is built on published studies of modified GRF(1-29) analogs. Studies have documented the pharmacokinetic improvements achieved through the four amino acid substitutions, demonstrating enhanced half-life and maintained receptor potency. Research published on the DAC (Drug Affinity Complex) version and the No DAC version provides comparative data on different GHRH analog strategies.

Ipamorelin Selectivity Studies

Raun et al. (Endocrinology, 1998) published pivotal research establishing ipamorelin’s selectivity profile among GHS-R agonists. This study demonstrated that ipamorelin produced GH release without significant effects on other pituitary hormones, making it one of the most selective ghrelin mimetics available for research.

GH Axis Synergy Research

Published research on GHRH and GHRP co-administration has demonstrated the synergistic nature of simultaneous GHRH-R and GHS-R activation. Bowers et al. (Endocrine Reviews, 1991) documented that combined GHRH + GHS-R agonist administration produces GH release 2-5 fold greater than either compound alone, providing the scientific rationale for the CJC-1295 ipamorelin blend approach.

QUALITY ASSURANCE

Quality & Testing Standards

HPLC & Mass Spectrometry

Both CJC-1295 No DAC and ipamorelin undergo individual HPLC and mass spectrometry analysis to verify identity, purity, and molecular weight.

Third-Party Verified

All components are independently tested at third-party USA-based analytical laboratories.

≥99% Purity Standard

Each component consistently meets or exceeds ≥99% purity as verified by HPLC for reliable dual-pathway research.

FAQ

Frequently Asked Questions About CJC-1295 No DAC + Ipamorelin

What is CJC-1295 No DAC + Ipamorelin used for in research?

This blend is used in preclinical research to study synergistic growth hormone release, dual-pathway GH axis activation (GHRH-R + GHS-R), pulsatile GH secretion, and IGF-1 axis regulation. It is sold for research use only.

What purity is VivePeptides CJC-1295 No DAC + Ipamorelin?

Each component is manufactured to ≥99% purity as verified by HPLC. Both CJC-1295 No DAC and ipamorelin are independently tested at USA-based analytical laboratories.

How should CJC-1295 No DAC + Ipamorelin be stored?

The lyophilized blend should be stored at -20°C, protected from light and moisture. Reconstituted solutions should be stored at 2–8°C and used within 7 days.

What is the difference between CJC-1295 with DAC and CJC-1295 No DAC?

CJC-1295 with DAC (Drug Affinity Complex) includes a maleimidopropionic acid linker that binds to serum albumin, dramatically extending half-life. CJC-1295 No DAC (Modified GRF 1-29) lacks this linker, resulting in a shorter half-life but producing more physiological pulsatile GH release patterns preferred for certain research applications.

Is VivePeptides CJC-1295 No DAC + Ipamorelin third-party tested?

Yes. Every lot undergoes independent third-party testing at USA-based laboratories. Each component is individually verified by HPLC and mass spectrometry. Results are available for qualified researchers.

Related Research Peptides

Explore other research-grade peptides available from VivePeptides. Each product meets the same rigorous purity and testing standards.

Tesamorelin

Full-length GHRH analog for growth hormone research

BPC-157

Gastric pentadecapeptide for tissue biology research

MOTS-c

Mitochondrial-derived peptide for metabolic research

Semaglutide

GLP-1 receptor agonist for metabolic pathway research

Explore More Research Peptides

All Peptides → · Tirzepatide · Retatrutide · NAD+ · GHK-Cu · Selank · SNAP-8 · BAC Water